Literature DB >> 3312526

Calcium antagonists in hypertension.

F R Bühler1, W Kiowski.   

Abstract

Calcium antagonists are potent arterial vasodilators with no long-term effect on sympathetic reflex activity or sodium and volume retention. This favourable haemodynamic profile makes them suitable for monotherapy of hypertension, where they act to reduce an enhanced, calcium-influx-dependent vasoconstrictor mechanism which may be brought about by altered smooth-muscle cation handling and increased intracellular concentrations of free calcium. Clinical studies have proved the efficacy, safety and acceptability of calcium antagonists alone or in combination with other drugs in uncomplicated hypertension; calcium antagonists are particularly effective in older patients, those with low renin levels and, possibly, black patients. These properties and the efficacy of calcium antagonists in the treatment of severe and accelerated hypertension or hypertensive emergencies make them a valuable addition to the drugs already available for the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312526

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  7 in total

1.  Patterns of Hypertension and their Implications for Therapy.

Authors:  J G Fodor
Journal:  Can Fam Physician       Date:  1989-10       Impact factor: 3.275

Review 2.  Choosing the optimum therapy for older hypertensive patients.

Authors:  W H Birkenhäger
Journal:  Drugs Aging       Date:  1991-01       Impact factor: 3.923

Review 3.  Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

Authors:  K Miller
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

4.  Diethyl 4-[5-(4-chloro-phen-yl)-1H-pyrazol-4-yl]-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxyl-ate.

Authors:  Hoong-Kun Fun; Wan-Sin Loh; A M Vijesh; Arun M Isloor; Shridhar Malladi
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-04-04

5.  1-[5-Acetyl-2,6-dimethyl-4-(5-phenyl-1H-pyrazol-3-yl)-1,4-dihydro-pyridin-3-yl]ethanone monohydrate.

Authors:  Arun M Islor; Shridhar Malladi; S Sundershan; Thomas Gerber; Eric Hosten; Richard Betz
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-10-20

6.  Dimethyl 2,6-dimethyl-4-{3-[4-(methyl-sulfan-yl)phen-yl]-1H-pyrazol-4-yl}-1,4-dihydro-pyridine-3,5-dicarboxyl-ate monohydrate.

Authors:  Arun M Islor; A M Vijesh; Thomas Gerber; Eric Hosten; Richard Betz
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-11-10

7.  Dimethyl 4-[3-(4-meth-oxy-phen-yl)-1-phenyl-1H-pyrazol-4-yl]-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxyl-ate dihydrate.

Authors:  Hoong-Kun Fun; Chin Wei Ooi; B Garudachari; Kammasandra Nanjunda Shivananda; Arun M Isloor
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.